Winning Strategies for CAR T, TCR, and TIL Therapies banner

The immunotherapy field is vibrant with rapid progress being made on the targeting of solid tumours and enhancing effector function. Novel platforms for creating off-the-shelf therapies including cell therapy and antibody-based approaches will be discussed. More than five CAR Ts, and more than 80 (bispecific) T cell engagers are in the clinic with new generations of exciting approaches currently in development that promise greater precision and safety.